{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:27:27Z","timestamp":1770326847928,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Serum prostate-specific antigen (PSA) is currently the most used biomarker in clinical practice for prostate cancer (PCa) detection. However, this biomarker has several drawbacks. In this work, an untargeted gas chromatography-mass spectrometry (GC-MS)-based metabolomic profiling of PCa cells was performed to prove the concept that metabolic alterations might differentiate PCa cell lines from normal prostate cell line. For that, we assessed the differences in volatile organic compounds (VOCs) profile in the extracellular medium (exometabolome) of four PCa cell lines and one normal prostate cell line at two pH values (pH 2 and 7) by GC-MS. Multivariate analysis revealed a panel of volatile metabolites that discriminated cancerous from normal prostate cells. The most altered metabolites included ketones, aldehydes and organic acids. Among these, we highlight pentadecane-2-one and decanoic acid, which were significantly increased in PCa compared to normal cells, and cyclohexanone, 4-methylheptan-2-one, 2-methylpentane-1,3-diol, 4-methylbenzaldehyde, 1-(3,5-dimethylfuran-2-yl)ethanone, methyl benzoate and nonanoic acid, which were significantly decreased in PCa cells. The PCa volatilome was markedly influenced by the VOCs extraction pH, though the discriminant capability was similar. Overall, our data suggest that VOCs monitoring has the potential to be used as a PCa screening methodology.<\/jats:p>","DOI":"10.1038\/s41598-018-23847-9","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T02:24:12Z","timestamp":1522290252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS"],"prefix":"10.1038","volume":"8","author":[{"given":"Ana Rita","family":"Lima","sequence":"first","affiliation":[]},{"given":"Ana Margarida","family":"Ara\u00fajo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-8364","authenticated-orcid":false,"given":"Joana","family":"Pinto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"given":"Maria de Lourdes","family":"Bastos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-4751","authenticated-orcid":false,"given":"M\u00e1rcia","family":"Carvalho","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-5700","authenticated-orcid":false,"given":"Paula","family":"Guedes de Pinho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"23847_CR1","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/1055-9965.EPI-15-1223","volume":"25","author":"RS Kelly","year":"2016","unstructured":"Kelly, R. S., Vander Heiden, M. G., Giovannucci, E. & Mucci, L. A. Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev 25, 887\u2013906, https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-1223 (2016).","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"23847_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics. CA Cancer J Clin 67, 7\u201330, https:\/\/doi.org\/10.3322\/caac.21387 (2017).","journal-title":"CA Cancer J Clin"},{"key":"23847_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4137\/BIC.S31802","volume":"8","author":"PO Gaudreau","year":"2016","unstructured":"Gaudreau, P. O., Stagg, J., Soulieres, D. & Saad, F. The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomark Cancer 8, 15\u201333, https:\/\/doi.org\/10.4137\/BIC.S31802 (2016).","journal-title":"Biomark Cancer"},{"key":"23847_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0090-4295(00)00637-3","volume":"56","author":"WJ Catalona","year":"2000","unstructured":"Catalona, W. J. et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56, 255\u2013260 (2000).","journal-title":"Urology"},{"key":"23847_CR5","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.1997.03540420048028","volume":"277","author":"WJ Catalona","year":"1997","unstructured":"Catalona, W. J., Smith, D. S. & Ornstein, D. K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng\/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277, 1452\u20131455 (1997).","journal-title":"JAMA"},{"key":"23847_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1464-410X.2003.04657.x","volume":"93","author":"MH Sokoloff","year":"2004","unstructured":"Sokoloff, M. H., Yang, X. J., Fumo, M., Mhoon, D. & Brendler, C. B. Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of 4.0 ng\/mL. BJU Int 93, 499\u2013502 (2004).","journal-title":"BJU Int"},{"key":"23847_CR7","doi-asserted-by":"crossref","unstructured":"Nadler, R. B. et al. Use of 2.6 ng\/ml prostate specific antigen prompt for biopsy in men older than 60 years. The Journal of urology 174, 2154-2157, discussion 2157 (2005).","DOI":"10.1097\/01.ju.0000181213.07447.8f"},{"key":"23847_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1158\/1940-6207.CAPR-08-0078","volume":"1","author":"MS Lucia","year":"2008","unstructured":"Lucia, M. S. et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) 1, 167\u2013173, https:\/\/doi.org\/10.1158\/1940-6207.CAPR-08-0078 (2008).","journal-title":"Cancer Prev Res (Phila)"},{"key":"23847_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349, 215\u2013224, https:\/\/doi.org\/10.1056\/NEJMoa030660 (2003).","journal-title":"N Engl J Med"},{"key":"23847_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.urolonc.2011.08.002","volume":"29","author":"BJ Trock","year":"2011","unstructured":"Trock, B. J. Application of metabolomics to prostate cancer. Urologic oncology 29, 572\u2013581, https:\/\/doi.org\/10.1016\/j.urolonc.2011.08.002 (2011).","journal-title":"Urologic oncology"},{"key":"23847_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4111\/kju.2011.52.2.79","volume":"52","author":"MJ Roberts","year":"2011","unstructured":"Roberts, M. J., Schirra, H. J., Lavin, M. F. & Gardiner, R. A. Metabolomics: a novel approach to early and noninvasive prostate cancer detection. Korean J Urol 52, 79\u201389, https:\/\/doi.org\/10.4111\/kju.2011.52.2.79 (2011).","journal-title":"Korean J Urol"},{"key":"23847_CR12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","volume":"360","author":"GL Andriole","year":"2009","unstructured":"Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360, 1310\u20131319, https:\/\/doi.org\/10.1056\/NEJMoa0810696 (2009).","journal-title":"N Engl J Med"},{"key":"23847_CR13","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schroder","year":"2009","unstructured":"Schroder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360, 1320\u20131328, https:\/\/doi.org\/10.1056\/NEJMoa0810084 (2009).","journal-title":"N Engl J Med"},{"key":"23847_CR14","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/sj.bjc.6605422","volume":"101","author":"EA Heijnsdijk","year":"2009","unstructured":"Heijnsdijk, E. A. et al. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. British journal of cancer 101, 1833\u20131838, https:\/\/doi.org\/10.1038\/sj.bjc.6605422 (2009).","journal-title":"British journal of cancer"},{"key":"23847_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer, V. A. & Force, U. S. P. S. T. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157, 120\u2013134, https:\/\/doi.org\/10.7326\/0003-4819-157-2-201207170-00459 (2012).","journal-title":"Ann Intern Med"},{"key":"23847_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.eururo.2015.04.008","volume":"68","author":"PJ Bostrom","year":"2015","unstructured":"Bostrom, P. J. et al. Genomic Predictors of Outcome in Prostate Cancer. Eur Urol 68, 1033\u20131044, https:\/\/doi.org\/10.1016\/j.eururo.2015.04.008 (2015).","journal-title":"Eur Urol"},{"key":"23847_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1373\/clinchem.2012.184598","volume":"59","author":"OA Aboud","year":"2013","unstructured":"Aboud, O. A. & Weiss, R. H. New opportunities from the cancer metabolome. Clinical chemistry 59, 138\u2013146, https:\/\/doi.org\/10.1373\/clinchem.2012.184598 (2013).","journal-title":"Clinical chemistry"},{"key":"23847_CR18","doi-asserted-by":"crossref","unstructured":"Monteiro, M. S., Carvalho, M., Bastos, M. d. L. & Pinho, P. G. In Identification and Data Processing Methods in Metabolomics Future Science Book Series, 166\u2013184 (FutureScience Ltd, 2015).","DOI":"10.4155\/fseb2013.14.178"},{"key":"23847_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.drudis.2010.06.012","volume":"15","author":"M Cuperlovic-Culf","year":"2010","unstructured":"Cuperlovic-Culf, M., Barnett, D. A., Culf, A. S. & Chute, I. Cell culture metabolomics: applications and future directions. Drug discovery today 15, 610\u2013621, https:\/\/doi.org\/10.1016\/j.drudis.2010.06.012 (2010).","journal-title":"Drug discovery today"},{"key":"23847_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.abb.2014.09.002","volume":"564","author":"A Halama","year":"2014","unstructured":"Halama, A. Metabolomics in cell culture\u2013a strategy to study crucial metabolic pathways in cancer development and the response to treatment. Archives of biochemistry and biophysics 564, 100\u2013109, https:\/\/doi.org\/10.1016\/j.abb.2014.09.002 (2014).","journal-title":"Archives of biochemistry and biophysics"},{"key":"23847_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1089\/omi.2012.0090","volume":"17","author":"A Zhang","year":"2013","unstructured":"Zhang, A., Sun, H., Xu, H., Qiu, S. & Wang, X. Cell metabolomics. Omics: a journal of integrative biology 17, 495\u2013501, https:\/\/doi.org\/10.1089\/omi.2012.0090 (2013).","journal-title":"Omics: a journal of integrative biology"},{"key":"23847_CR22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/pros.22665","volume":"73","author":"KR Keshari","year":"2013","unstructured":"Keshari, K. R. et al. Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate 73, 1171\u20131181, https:\/\/doi.org\/10.1002\/pros.22665 (2013).","journal-title":"Prostate"},{"key":"23847_CR23","doi-asserted-by":"publisher","unstructured":"Monteiro, M. et al. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients. J Cell Mol Med, https:\/\/doi.org\/10.1111\/jcmm.13132 (2017).","DOI":"10.1111\/jcmm.13132"},{"key":"23847_CR24","doi-asserted-by":"publisher","first-page":"981458","DOI":"10.1155\/2015\/981458","volume":"2015","author":"K Schmidt","year":"2015","unstructured":"Schmidt, K. & Podmore, I. Current Challenges in Volatile Organic Compounds Analysis as Potential Biomarkers of Cancer. Journal of biomarkers 2015, 981458, https:\/\/doi.org\/10.1155\/2015\/981458 (2015).","journal-title":"Journal of biomarkers"},{"key":"23847_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/jb\/mvr090","volume":"150","author":"M Shirasu","year":"2011","unstructured":"Shirasu, M. & Touhara, K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. Journal of biochemistry 150, 257\u2013266, https:\/\/doi.org\/10.1093\/jb\/mvr090 (2011).","journal-title":"Journal of biochemistry"},{"key":"23847_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/codi.13271","volume":"18","author":"M Di Lena","year":"2016","unstructured":"Di Lena, M., Porcelli, F. & Altomare, D. F. Volatile organic compounds as new biomarkers for colorectal cancer: a review. Colorectal Dis 18, 654\u2013663, https:\/\/doi.org\/10.1111\/codi.13271 (2016).","journal-title":"Colorectal Dis"},{"key":"23847_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nrmicro1177","volume":"3","author":"DB Kell","year":"2005","unstructured":"Kell, D. B. et al. Metabolic footprinting and systems biology: the medium is the message. Nat Rev Microbiol 3, 557\u2013565, https:\/\/doi.org\/10.1038\/nrmicro1177 (2005).","journal-title":"Nat Rev Microbiol"},{"key":"23847_CR28","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/elps.201200605","volume":"34","author":"Z Leon","year":"2013","unstructured":"Leon, Z., Garcia-Canaveras, J. C., Donato, M. T. & Lahoz, A. Mammalian cell metabolomics: experimental design and sample preparation. Electrophoresis 34, 2762\u20132775, https:\/\/doi.org\/10.1002\/elps.201200605 (2013).","journal-title":"Electrophoresis"},{"key":"23847_CR29","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1039\/C4AN00583J","volume":"139","author":"MJ Nunes de Paiva","year":"2014","unstructured":"Nunes de Paiva, M. J., Menezes, H. C. & de Lourdes Cardeal, Z. Sampling and analysis of metabolomes in biological fluids. Analyst 139, 3683\u20133694, https:\/\/doi.org\/10.1039\/c4an00583j (2014).","journal-title":"Analyst"},{"key":"23847_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep43969","volume":"7","author":"CL Silva","year":"2017","unstructured":"Silva, C. L., Perestrelo, R., Silva, P., Tomas, H. & Camara, J. S. Volatile metabolomic signature of human breast cancer cell lines. Sci Rep 7, 43969, https:\/\/doi.org\/10.1038\/srep43969 (2017).","journal-title":"Sci Rep"},{"key":"23847_CR31","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.jchromb.2010.01.022","volume":"878","author":"D Poli","year":"2010","unstructured":"Poli, D. et al. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC\/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 878, 2643\u20132651, https:\/\/doi.org\/10.1016\/j.jchromb.2010.01.022 (2010).","journal-title":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"},{"key":"23847_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cca.2014.04.030","volume":"436","author":"J Li","year":"2014","unstructured":"Li, J. et al. Investigation of potential breath biomarkers for the early diagnosis of breast cancer using gas chromatography-mass spectrometry. Clinica chimica acta; international journal of clinical chemistry 436, 59\u201367, https:\/\/doi.org\/10.1016\/j.cca.2014.04.030 (2014).","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"key":"23847_CR33","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/lary.24463","volume":"124","author":"N Leunis","year":"2014","unstructured":"Leunis, N. et al. Application of an electronic nose in the diagnosis of head and neck cancer. The Laryngoscope 124, 1377\u20131381, https:\/\/doi.org\/10.1002\/lary.24463 (2014).","journal-title":"The Laryngoscope"},{"key":"23847_CR34","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1021\/ac4010309","volume":"85","author":"S Kumar","year":"2013","unstructured":"Kumar, S. et al. Selected ion flow tube mass spectrometry analysis of exhaled breath for volatile organic compound profiling of esophago-gastric cancer. Analytical chemistry 85, 6121\u20136128, https:\/\/doi.org\/10.1021\/ac4010309 (2013).","journal-title":"Analytical chemistry"},{"key":"23847_CR35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/bjs.8942","volume":"100","author":"DF Altomare","year":"2013","unstructured":"Altomare, D. F. et al. Exhaled volatile organic compounds identify patients with colorectal cancer. The British journal of surgery 100, 144\u2013150, https:\/\/doi.org\/10.1002\/bjs.8942 (2013).","journal-title":"The British journal of surgery"},{"key":"23847_CR36","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/s11306-013-0523-z","volume":"9","author":"T Abaffy","year":"2013","unstructured":"Abaffy, T., Moller, M. G., Riemer, D. D., Milikowski, C. & DeFazio, R. A. Comparative analysis of volatile metabolomics signals from melanoma and benign skin: a pilot study. Metabolomics: Official journal of the Metabolomic Society 9, 998\u20131008, https:\/\/doi.org\/10.1007\/s11306-013-0523-z (2013).","journal-title":"Metabolomics: Official journal of the Metabolomic Society"},{"key":"23847_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-13-72","volume":"13","author":"P Mochalski","year":"2013","unstructured":"Mochalski, P. et al. Release and uptake of volatile organic compounds by human hepatocellular carcinoma cells (HepG2) in vitro. Cancer cell international 13, 72, https:\/\/doi.org\/10.1186\/1475-2867-13-72 (2013).","journal-title":"Cancer cell international"},{"key":"23847_CR38","doi-asserted-by":"publisher","first-page":"e0143283","DOI":"10.1371\/journal.pone.0143283","volume":"10","author":"T Khalid","year":"2015","unstructured":"Khalid, T. et al. Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. PloS one 10, e0143283, https:\/\/doi.org\/10.1371\/journal.pone.0143283 (2015).","journal-title":"PloS one"},{"key":"23847_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1109\/JSEN.2009.2035771","volume":"10","author":"PW Steve Smith","year":"2010","unstructured":"Steve Smith, P. W., Redding, J., Ratcliffe, N. M. & Chris S. J. Probert. Application of Similarity Coefficients to Predict Disease Using Volatile Organic Compounds. IEEE SENSORS JOURNAL 10, 92\u201396, https:\/\/doi.org\/10.1109\/JSEN.2009.2035771 (2010).","journal-title":"IEEE SENSORS JOURNAL"},{"key":"23847_CR40","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3892\/or.2016.4997","volume":"36","author":"S Huang","year":"2016","unstructured":"Huang, S. et al. Acidic extracellular pH promotes prostate cancer bone metastasis by enhancing PC-3 stem cell characteristics, cell invasiveness and VEGF-induced vasculogenesis of BM-EPCs. Oncol Rep 36, 2025\u20132032, https:\/\/doi.org\/10.3892\/or.2016.4997 (2016).","journal-title":"Oncol Rep"},{"key":"23847_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/humu.21138","volume":"31","author":"G Marcias","year":"2010","unstructured":"Marcias, G. et al. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Human mutation 31, 74\u201380, https:\/\/doi.org\/10.1002\/humu.21138 (2010).","journal-title":"Human mutation"},{"key":"23847_CR42","doi-asserted-by":"publisher","first-page":"D801","DOI":"10.1093\/nar\/gks1065","volume":"41","author":"DS Wishart","year":"2013","unstructured":"Wishart, D. S. et al. HMDB 3.0\u2013The Human Metabolome Database in 2013. Nucleic acids research 41, D801\u2013807, https:\/\/doi.org\/10.1093\/nar\/gks1065 (2013).","journal-title":"Nucleic acids research"},{"key":"23847_CR43","doi-asserted-by":"publisher","first-page":"D521","DOI":"10.1093\/nar\/gkl923","volume":"35","author":"DS Wishart","year":"2007","unstructured":"Wishart, D. S. et al. HMDB: the Human Metabolome Database. Nucleic acids research 35, D521\u2013526, https:\/\/doi.org\/10.1093\/nar\/gkl923 (2007).","journal-title":"Nucleic acids research"},{"key":"23847_CR44","doi-asserted-by":"publisher","first-page":"D603","DOI":"10.1093\/nar\/gkn810","volume":"37","author":"DS Wishart","year":"2009","unstructured":"Wishart, D. S. et al. HMDB: a knowledgebase for the human metabolome. Nucleic acids research 37, D603\u2013610, https:\/\/doi.org\/10.1093\/nar\/gkn810 (2009).","journal-title":"Nucleic acids research"},{"key":"23847_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11306-006-0038-y","volume":"3","author":"D Zimmermann","year":"2007","unstructured":"Zimmermann, D., Hartmann, M., Moyer, M. P., Nolte, J. & Baumbach, J. I. Determination of volatile products of human colon cell line metabolism by GC\/MS analysis. Metabolomics: Official journal of the Metabolomic Society 3, 13\u201317, https:\/\/doi.org\/10.1007\/s11306-006-0038-y (2007).","journal-title":"Metabolomics: Official journal of the Metabolomic Society"},{"key":"23847_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/CBM-2010-0182","volume":"7","author":"A Sponring","year":"2010","unstructured":"Sponring, A. et al. Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. Cancer biomarkers: section A of Disease markers 7, 153\u2013161, https:\/\/doi.org\/10.3233\/CBM-2010-0182 (2010).","journal-title":"Cancer biomarkers: section A of Disease markers"},{"key":"23847_CR47","unstructured":"Wojciech, F. et al. A compendium of volatile organic compounds (VOCs) released by human cell lines. Current medicinal chemistry (2016)."},{"key":"23847_CR48","doi-asserted-by":"publisher","first-page":"016004","DOI":"10.1088\/1752-7155\/3\/1\/016004","volume":"3","author":"S Erhart","year":"2009","unstructured":"Erhart, S. et al. 3-Heptanone as a potential new marker for valproic acid therapy. J Breath Res 3, 016004, https:\/\/doi.org\/10.1088\/1752-7155\/3\/1\/016004 (2009).","journal-title":"J Breath Res"},{"key":"23847_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11306-016-1055-0","volume":"12","author":"B Madhu","year":"2016","unstructured":"Madhu, B., Shaw, G. L., Warren, A. Y., Neal, D. E. & Griffiths, J. R. Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy. Metabolomics: Official journal of the Metabolomic Society 12, 120, https:\/\/doi.org\/10.1007\/s11306-016-1055-0 (2016).","journal-title":"Metabolomics: Official journal of the Metabolomic Society"},{"key":"23847_CR50","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1021\/cr300174a","volume":"112","author":"M Hakim","year":"2012","unstructured":"Hakim, M. et al. Volatile organic compounds of lung cancer and possible biochemical pathways. Chemical reviews 112, 5949\u20135966, https:\/\/doi.org\/10.1021\/cr300174a (2012).","journal-title":"Chemical reviews"},{"key":"23847_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-8-17","volume":"8","author":"W Filipiak","year":"2008","unstructured":"Filipiak, W. et al. Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro. Cancer cell international 8, 17, https:\/\/doi.org\/10.1186\/1475-2867-8-17 (2008).","journal-title":"Cancer cell international"},{"key":"23847_CR52","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/bjc.2014.411","volume":"111","author":"MP Davies","year":"2014","unstructured":"Davies, M. P. et al. Unique volatolomic signatures of TP53 and KRAS in lung cells. British journal of cancer 111, 1213\u20131221, https:\/\/doi.org\/10.1038\/bjc.2014.411 (2014).","journal-title":"British journal of cancer"},{"key":"23847_CR53","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.freeradbiomed.2011.11.033","volume":"52","author":"G Muzio","year":"2012","unstructured":"Muzio, G., Maggiora, M., Paiuzzi, E., Oraldi, M. & Canuto, R. A. Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 52, 735\u2013746, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2011.11.033 (2012).","journal-title":"Free Radic Biol Med"},{"key":"23847_CR54","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1038\/bjc.2014.201","volume":"110","author":"J Yan","year":"2014","unstructured":"Yan, J., De Melo, J., Cutz, J. C., Aziz, T. & Tang, D. Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis. British journal of cancer 110, 2593\u20132603, https:\/\/doi.org\/10.1038\/bjc.2014.201 (2014).","journal-title":"British journal of cancer"},{"key":"23847_CR55","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/sj.bjc.6605810","volume":"103","author":"G Peng","year":"2010","unstructured":"Peng, G. et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. British journal of cancer 103, 542\u2013551, https:\/\/doi.org\/10.1038\/sj.bjc.6605810 (2010).","journal-title":"British journal of cancer"},{"key":"23847_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11306-017-1251-6","volume":"13","author":"R Taware","year":"2017","unstructured":"Taware, R. et al. Investigation of urinary volatomic alterations in head and neck cancer: a non-invasive approach towards diagnosis and prognosis. Metabolomics: Official journal of the Metabolomic Society 13, 111, https:\/\/doi.org\/10.1007\/s11306-017-1251-6 (2017).","journal-title":"Metabolomics: Official journal of the Metabolomic Society"},{"key":"23847_CR57","first-page":"173","volume":"5","author":"A Wallqvist","year":"2003","unstructured":"Wallqvist, A. et al. Mining the NCI screening database: explorations of agents involved in cell cycle regulation. Progress in cell cycle research 5, 173\u2013179 (2003).","journal-title":"Progress in cell cycle research"},{"key":"23847_CR58","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1039\/C3CS60329F","volume":"43","author":"H Haick","year":"2014","unstructured":"Haick, H., Broza, Y. Y., Mochalski, P., Ruzsanyi, V. & Amann, A. Assessment, origin, and implementation of breath volatile cancer markers. Chemical Society reviews 43, 1423\u20131449, https:\/\/doi.org\/10.1039\/c3cs60329f (2014).","journal-title":"Chemical Society reviews"},{"key":"23847_CR59","doi-asserted-by":"publisher","unstructured":"Tang, H. et al. Determination of volatile organic compounds exhaled by cell lines derived from hematological malignancies. Biosci Rep 37, https:\/\/doi.org\/10.1042\/BSR20170106 (2017).","DOI":"10.1042\/BSR20170106"},{"key":"23847_CR60","doi-asserted-by":"publisher","first-page":"154","DOI":"10.7150\/thno.7560","volume":"4","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. Identification of volatile biomarkers of gastric cancer cells and ultrasensitive electrochemical detection based on sensing interface of Au-Ag alloy coated MWCNTs. Theranostics 4, 154\u2013162, https:\/\/doi.org\/10.7150\/thno.7560 (2014).","journal-title":"Theranostics"},{"key":"23847_CR61","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00216-011-5098-9","volume":"401","author":"H Wu","year":"2011","unstructured":"Wu, H. et al. GC\/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal Bioanal Chem 401, 635\u2013646, https:\/\/doi.org\/10.1007\/s00216-011-5098-9 (2011).","journal-title":"Anal Bioanal Chem"},{"key":"23847_CR62","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1021\/pr500409q","volume":"13","author":"X Zang","year":"2014","unstructured":"Zang, X. et al. Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics. Journal of proteome research 13, 3444\u20133454, https:\/\/doi.org\/10.1021\/pr500409q (2014).","journal-title":"Journal of proteome research"},{"key":"23847_CR63","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jchromb.2013.05.007","volume":"931","author":"J Kwak","year":"2013","unstructured":"Kwak, J. et al. Volatile biomarkers from human melanoma cells. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 931, 90\u201396, https:\/\/doi.org\/10.1016\/j.jchromb.2013.05.007 (2013).","journal-title":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"},{"key":"23847_CR64","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1039\/C5MB00019J","volume":"11","author":"Z Huang","year":"2015","unstructured":"Huang, Z. et al. Effects of culture media on metabolic profiling of the human gastric cancer cell line SGC7901. Mol Biosyst 11, 1832\u20131840, https:\/\/doi.org\/10.1039\/c5mb00019j (2015).","journal-title":"Mol Biosyst"},{"key":"23847_CR65","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.ejca.2014.04.011","volume":"50","author":"M Monteiro","year":"2014","unstructured":"Monteiro, M. et al. Analysis of volatile human urinary metabolome by solid-phase microextraction in combination with gas chromatography-mass spectrometry for biomarker discovery: application in a pilot study to discriminate patients with renal cell carcinoma. Eur J Cancer 50, 1993\u20132002, https:\/\/doi.org\/10.1016\/j.ejca.2014.04.011 (2014).","journal-title":"Eur J Cancer"},{"key":"23847_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.aca.2015.10.001","volume":"900","author":"A Mastrangelo","year":"2015","unstructured":"Mastrangelo, A., Ferrarini, A., Rey-Stolle, F., Garcia, A. & Barbas, C. From sample treatment to biomarker discovery: A tutorial for untargeted metabolomics based on GC-(EI)-Q-MS. Analytica chimica acta 900, 21\u201335, https:\/\/doi.org\/10.1016\/j.aca.2015.10.001 (2015).","journal-title":"Analytica chimica acta"},{"key":"23847_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-395","volume":"11","author":"T Pluskal","year":"2010","unstructured":"Pluskal, T., Castillo, S., Villar-Briones, A. & Oresic, M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 11, 395, https:\/\/doi.org\/10.1186\/1471-2105-11-395 (2010).","journal-title":"BMC Bioinformatics"},{"key":"23847_CR68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.eururo.2010.01.035","volume":"58","author":"F Jentzmik","year":"2010","unstructured":"Jentzmik, F. et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 58, 12\u201318, https:\/\/doi.org\/10.1016\/j.eururo.2010.01.035 (2010). discussion 20-11.","journal-title":"Eur Urol"},{"key":"23847_CR69","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ijnurstu.2012.01.015","volume":"49","author":"L Berben","year":"2012","unstructured":"Berben, L., Sereika, S. M. & Engberg, S. Effect size estimation: methods and examples. International journal of nursing studies 49, 1039\u20131047, https:\/\/doi.org\/10.1016\/j.ijnurstu.2012.01.015 (2012).","journal-title":"International journal of nursing studies"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23847-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T04:05:25Z","timestamp":1671595525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23847-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23847"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23847-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"16 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5539"}}